Compare NNN & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNN | IBRX |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 7.5B |
| IPO Year | 1995 | 2015 |
| Metric | NNN | IBRX |
|---|---|---|
| Price | $43.50 | $7.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $44.50 | $12.57 |
| AVG Volume (30 Days) | 1.4M | ★ 14.3M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.47% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $926,213,000.00 | $113,288,000.00 |
| Revenue This Year | $5.14 | $88.59 |
| Revenue Next Year | $4.64 | $131.15 |
| P/E Ratio | $21.21 | ★ N/A |
| Revenue Growth | 6.55 | ★ 668.31 |
| 52 Week Low | $38.90 | $1.83 |
| 52 Week High | $46.03 | $12.43 |
| Indicator | NNN | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.08 | 44.66 |
| Support Level | $41.61 | $2.22 |
| Resistance Level | $45.67 | $8.28 |
| Average True Range (ATR) | 0.66 | 0.57 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 13.08 | 20.17 |
NNN REIT Inc is a real estate investment trust that acquires, owns, invests in, and develops high-quality properties mainly leased under long-term net leases with minimal capital expenditure requirements. The company focuses mainly on retail properties, with a portfolio including convenience stores, automotive service properties, restaurants, theatres, entertainment venues, dealerships, and other retail-related assets. Primary business objectives emphasize retail properties, and it may invest in a wide variety of property and tenant types, leases, mortgages, loans secured by personal property, loans secured by partnership or membership interests, and securities of other REITs or other issuers.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.